Malaria Clinical Trial
Official title:
Evaluating the Impact of Enhanced Health Facility-based Care for Malaria and Febrile Illnesses in Children in Tororo, Uganda
The investigators propose to assess whether an intervention to build capacity and improve delivery of drugs and diagnostics at government-run health facilities improves the health of children and quality of care delivered, as compared to 'standard care' currently available at health facilities, supplemented by services provided through the private sector and community-based interventions. The target population will be divided into 20 clusters, defined as the catchment area of lower-level public health facilities. Clusters will be randomized to the health facility intervention (HFI) or to standard care delivered from government-run health facilities, supplemented by services provided through the private sector and community-based interventions. The intervention is designed to address barriers to delivering quality care at health centers and will focus on three components: (1) training in-charges in health center management, (2) providing training to health workers in fever case management and patient-centered services, and (3) ensuring adequate supplies of artemether-lumefantrine and RDTs. Outcomes will be measured in three distinct populations: (1) cross-sectional surveys of children under 15 years randomly selected from households within the clusters; (2) a cohort of children under five randomly selected from households within the clusters and followed for 2 years; and (3) patients attending all government-run health facilities, including children under five and their caregivers participating in exit interviews on selected days every six months. The primary outcome of the study is prevalence of anemia in children under five.
| Status | Completed |
| Enrollment | 25000 |
| Est. completion date | July 2013 |
| Est. primary completion date | April 2013 |
| Accepts healthy volunteers | Accepts Healthy Volunteers |
| Gender | Both |
| Age group | N/A to 15 Years |
| Eligibility |
FOR THE COHORT STUDY Inclusion Criteria: 1. age < 5 years 2. agreement of parents or guardians to provide informed consent Exclusion Criteria: 1) intention to move during the follow-up period FOR THE CROSS-SECTIONAL SURVEY: Inclusion Criteria: 1. age < 15 years 2. agreement of parents or guardians to provide informed consent 3. agreement of a child aged 8 years or older to provide assent. Exclusion Criterion: 1) inability to locate the child. |
Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Health Services Research
| Country | Name | City | State |
|---|---|---|---|
| Uganda | Infectious Diseases Research Collaboration | Kampala |
| Lead Sponsor | Collaborator |
|---|---|
| Uganda Malaria Surveillance Project | Infectious Diseases Research Collaboration, Uganda, London School of Hygiene and Tropical Medicine, University of California, San Francisco |
Uganda,
Hopkins H, Talisuna A, Whitty CJ, Staedke SG. Impact of home-based management of malaria on health outcomes in Africa: a systematic review of the evidence. Malar J. 2007 Oct 8;6:134. Review. — View Citation
Staedke SG, Mwebaza N, Kamya MR, Clark TD, Dorsey G, Rosenthal PJ, Whitty CJ. Home management of malaria with artemether-lumefantrine compared with standard care in urban Ugandan children: a randomised controlled trial. Lancet. 2009 May 9;373(9675):1623-31. doi: 10.1016/S0140-6736(09)60328-7. Epub 2009 Apr 9. — View Citation
| Type | Measure | Description | Time frame | Safety issue |
|---|---|---|---|---|
| Other | Antimalarial treatment incidence density for children under five in the cohort study | Number of antimalarial treatments given for treatment of fever/malaria over the period of follow-up | 2 years | No |
| Other | Inappropriate treatment of malaria in children under five in the Patient Exit Interviews | Proportion of children under five with suspected malaria and a negative RDT result who are inappropriately given an ACT + Proportion of children under five with suspected malaria and a positive RDT result who are not prescribed an ACT. | Every six months | No |
| Primary | Prevalence of anemia in children under five in the cross-sectional surveys | Proportion of hemoglobin measurements < 11.0 g/dL as measured in cross sectional surveys. Anemia will be classified according to severity: mild (Hb 8.0 - 10.9), moderate (Hb 5.0 - 7.9), severe (Hb < 5.0). | annually | No |
| Secondary | Prevalence of parasitemia in children under five in the cross-sectional surveys | Proportion of thick blood smears that are positive for asexual parasites | annually | No |
| Secondary | All-cause mortality | Probability of dying between birth and five years of age, expressed per 1,000 live births | Annually | No |
| Secondary | Incidence of hospitalizations in children under five in the cohort study | Overnight admission to a hospital or clinic | two years | No |
| Secondary | Incidence of illness episodes in children under five in the cohort study | Episode of illness as reported by primary caregiver | Two years | No |
| Secondary | Incidence of febrile episodes in children under five in the cohort study | Episode of illness associated with fever as reported by primary caregiver | Two years | No |
| Secondary | Prompt effective treatment of fever in children under five in the cohort study | Proportion of children with fever treated within 24 hours of onset of symptoms with an ACT | Two years | Yes |
| Secondary | Incidence of serious adverse events in children under five in the cohort study | Any experience that results in death, life-threatening experience, hospitalization, persistent or significant disability or incapacity, or specific medical or surgical intervention to prevent one of the other serious outcomes | Two years | Yes |
| Secondary | Prompt effective treatment of malaria in children under five in the cohort study | Proportion of children with malaria (confirmed by a parasitological test) treated within 24 hours of onset of symptoms with an ACT | Two years | No |
| Secondary | Appropriate treatment of malaria in children under five in the Patient Exit Interviews | Proportion of children under five with suspected malaria and a positive RDT result who are appropriately given an ACT + Proportion of children under five with suspected malaria and a negative RDT result who are not prescribed an ACT | Every six months | No |
| Secondary | Inappropriate treatment of malaria in children under five in the Patient Exit Interviews | Proportion of children under five with suspected malaria and a positive RDT result who are inappropriately given a non-ACT regimen | Every six months | No |
| Secondary | Patient satisfaction with health care in caregivers of children under five in the Patient Exit Interviews | Proportion of patients indicating they were satisfied with care provided at the health center in exit interviews | Every six months | No |
| Secondary | Patient attendance in the Health facility surveillance | Total number of patients attending health facilities and their characteristics, including age, sex,village of residence, and diagnosis | Every two months | No |
| Secondary | Stock-outs of ACTs in the Health facility surveillance | Days per month that AL supplied by NMS via the district is not available | Every two months | No |
| Secondary | Knowledge questionnaire scores for Health workers | Proportion of questions answered correctly by clinicians following training in fever case management | Annually | No |
| Secondary | Prevalence of anemia in children aged 5-15years in the cross-sectional surveys | Proportion of hemoglobin measurements < 11.0 g/dL as measured in cross sectional surveys. Anemia will be classified according to severity: mild (Hb 8.0 - 10.9), moderate (Hb 5.0 - 7.9), severe (Hb < 5.0). | annually | No |
| Status | Clinical Trial | Phase | |
|---|---|---|---|
| Completed |
NCT04601714 -
Baseline Cohort Malaria Morbidity Study
|
||
| Withdrawn |
NCT04020653 -
A Study to Assess the Safety and Efficacy of 5-aminolevulinic Acid Hydrochloride (5-ALA HCl) and Sodium Ferrous Citrate (SFC) Added on Artemisinin-based Combination Therapy (ACT) in Adult Patients With Uncomplicated Malaria
|
Phase 2 | |
| Terminated |
NCT04368910 -
Safety and Efficacy of Pyronaridine Artesunate Vs Chloroquine in Children and Adult Patients With Acute Vivax Malaria
|
Phase 3 | |
| Completed |
NCT03641339 -
Defining Skin Immunity of a Bite of Key Insect Vectors in Humans
|
N/A | |
| Completed |
NCT02544048 -
Markers of T Cell Suppression: Antimalarial Treatment and Vaccine Responses in Healthy Malian Adults
|
||
| Completed |
NCT00527163 -
Role of Nitric Oxide in Malaria
|
||
| Not yet recruiting |
NCT05934318 -
L-ArGinine to pRevent advErse prEgnancy Outcomes (AGREE)
|
N/A | |
| Active, not recruiting |
NCT04704674 -
Community Dynamics of Malaria Transmission in Humans and Mosquitoes in Fleh-la and Marshansue, Salala District, Bong County, Liberia
|
||
| Completed |
NCT03276962 -
Efficacy, Safety and Immunogenicity Study of GSK Biologicals' Candidate Malaria Vaccine (SB257049) Evaluating Schedules With or Without Fractional Doses, Early Dose 4 and Yearly Doses, in Children 5-17 Months of Age
|
Phase 2 | |
| Completed |
NCT04966871 -
Safety, Tolerability and Efficacy of PfSPZ Vaccine Against Heterologous CHMI in US Malaria naïve Adults
|
Phase 1 | |
| Completed |
NCT00289185 -
Study of Safety, Immunogenicity and Efficacy of a Candidate Malaria Vaccine in Tanzanian Infants
|
Phase 2 | |
| Recruiting |
NCT03937817 -
Collection of Human Biospecimens for Basic and Clinical Research Into Globin Variants
|
||
| Active, not recruiting |
NCT06153862 -
Africa Ready Malaria Screening
|
N/A | |
| Completed |
NCT04545905 -
Antenatal Care as a Platform for Malaria Surveillance: Utilizing Community Prevalence Measures From the New Nets Project to Validate ANC Surveillance of Malaria in Burkina Faso
|
||
| Recruiting |
NCT06278181 -
Diabetes, Metabolic Syndrome and Risk of Malaria in Cameroon
|
||
| Completed |
NCT02909712 -
Cardiac Safety of Dihydroartemisinin-Piperaquine Amongst Pregnant Women in Tanzania
|
Phase 2 | |
| Completed |
NCT02793622 -
Prevention of Malaria in HIV-uninfected Pregnant Women and Infants
|
Phase 3 | |
| Withdrawn |
NCT02793388 -
A Trial on Supervised Primaquine Use in Ethiopia
|
Phase 4 | |
| Withdrawn |
NCT02793414 -
Diagnostic Utility of Volatile Organic Compounds in Human Breath for Acute Clinical Malaria in Ethiopia
|
||
| Completed |
NCT02605720 -
Cardiac Safety of Repeated Doses of Dihydroartemisinin-Piperaquine for the Use in Mass Treatment Campaigns
|
Phase 3 |